摘要
目的:观察复方苦参注射液联合化疗治疗晚期非小细胞肺癌的疗效。方法:将108例中晚期非小细胞肺癌患者随机分为治疗组(复方苦参注射液+化疗组)和对照组(化疗组)。对照组应用用紫杉醇、顺铂联合化疗,治疗组同时加用复方苦参注射液,15 m L·d-1,静脉滴注,连用14 d。结果:治疗组、对照组有效率分别为53.57%和36.54%,两组比较,差异有统计学意义(P<0.05)。治疗组、对照组疾病控制率分别为82.14%和67.31%,两组比较,差异有统计学意义(P<0.05)。治疗组、对照组KPS评分提高率分别为51.8%和34.6%,两组比较,差异有统计学意义(P<0.05);稳定率分别为83.9%和71.2%,两组比较,差异有统计学意义(P<0.05)。结论:复方苦参注射液联合化疗治疗晚期非小细胞肺癌可能提高近期疗效、改善生活质量。
Objective： To evaluate the clinical effect of compound Kushen injection combined with chemotherapy on advanced non-small cell lung cancer. Methods ： 108 cases of advanced no-small cell lung cancer were randomly divided into the treatment group （ compound Kushen injection plus chemotherapy） and the control group（chemotherapy）. The control group received the chemotherapy of paclitaxel and cisplatin, and the treatment group received the chemotherapy and compound Kushen injection, 15mL one day, intravenous drip, con- tinuous application of 14 days. Results ： The effective rate of the treatment group and the control group were 53.57% and 36.54% re- spectively, and the difference was statistically significant （ P 〈 0.05 ）. Disease control rate in the control group and the control group were 82.14% and 67.31% respectively,the difference was statistically significant （ P 〈 0.05 ）. The KPS score increasing rate in the treatment group and the control group were 51.8 % and 34.6% respectively, the difference was statistically significant （ P 〈 0.05 ） ; and the stability rate was 83.9% and 71.2% respectively,the difference was statistically significant （P 〈 0.05 ）. Conclusion： The treat- ment of advanced no-small cell lung cancer with compound Kushen injection plus chemotherapy can enhance the near future therapeutic effect, improve quality of life.
出处
《中医学报》
CAS
2015年第12期1710-1711,共2页
Acta Chinese Medicine
关键词
非小细胞肺癌
复方苦参注射液
紫杉醇
顺铂
non-small lung cancer
compound Kushen injection
paclitaxel
cisplatin
